Open AccessRetrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy
Author(s) -
Haixing Mai,
Mei Guo-Hui,
Fukun Zhao,
Botao Li,
Yongyong Tang,
Bin Zhang,
Xiaoqin Xu,
Lijun Chen
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.180609
Subject(s) - medicine , renal cell carcinoma , sorafenib , sunitinib , nephrectomy , clinical endpoint , urology , cytokine induced killer cell , progression free survival , gastroenterology , metastasis , oncology , retrospective cohort study , surgery , kidney , overall survival , hepatocellular carcinoma , cancer , immunology , clinical trial , immune system , cd3 , cd8
Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC). We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy.